Self-organizing molecular field analysis on pyridazine analogues as protein tyrosine phosphatase 1B (PTP 1B) inhibitors

Letters in Drug Design and Discovery

Volumn 7, Issue 6, 2010, Pages 395-401

  Thareja, Suresh ^a   Aggarwal, Saurabh ^a   Bhardwaj, Tilak Raj ^a,b   Kumar, Manoj ^a  

^a PANJAB UNIVERSITY   (India)

^b ISF COLLEGE OF PHARMACY   (India)

Author keywords

3D QSAR; Insulin; NIDDM; PTP 1B; Pyridazine; SOMFA

Indexed keywords

ANTIDIABETIC AGENT; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; PYRIDAZINE DERIVATIVE;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; DRUG STRUCTURE; ELECTROSTATIC PRECIPITATION; ENZYME INHIBITION; MOLECULAR MODEL; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SELF ORGANIZING MOLECULAR FIELD ANALYSIS; THREE DIMENSIONAL IMAGING;

EID: 77954708887     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018010791306605     Document Type: Article

References (30)

1. Klabunde, T.; Wendt, K. U.; Kadereit, D.; Brachvogel, V.; Burger, H. J.; Herling, A. W.; Oikonomakos, N. G.; Kosmopoulou, M. N.; Schmoll, D.; Sarubbi, E.; von, R. E.; Schonafinger, K.; Defossa, E. Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. J. Med. Chem., 2005, 48, 6178-6193.
2. Liu, K.; Xu, L.; Berger, J. P.; MacNaul, K. L.; Zhou, G.; Doebber, T. W.; Forrest, M. J.; Moller, D. E.; Jones, A. B. Discovery of a novel series of peroxisome proliferator-ctivated receptor/dual agonists for the treatment of type 2 diabetes and dyslipidemia. J. Med. Chem., 2005, 48, 2262-2265.
3. Liu, W.; Liu, K.; Wood, H. B.; McCann, M. E.; Doebber, T. W.; Chang, C.H.; Akiyama, T. E.; Einstein, M.; Berger, J. P.; Meinke, P.T. Discovery of a peroxisome proliferator activated receptor (PPAR) modulator with balanced PPAR activity for the treatment of type 2 diabetes and dyslipidemia. J. Med. Chem., 2009, 52, 4443-4453.
4. Vats, R. K.; Kumar, V.; Kothari, A.; Mital, A; Ramachandaran. U. Emerging targets for diabetes. Curr. Sci., 2005, 88, 241-249.
5. Bhattarai, B. R.; Shrestha, S.; Ham, S.W.; Kim, K.R.; Cheon, H.G.; Lee, K.H.; Cho H. 2-O-Carboxymethylpyrogallol derivatives as PTP1B inhibitors with anti hyperglycemic activity. Bioorg. Med. Chem. Lett., 2007, 17, 5357-5360.
6. Liu, G. Protein tyrosine phosphatases 1B (PTP 1B) inhibition: opportunities and challenges. Curr. Med. Chem., 2003, 10, 1407-1421.
7. Byon, J.C.H; Kusari, J.; Kusari, A.B. Protein tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Mol. Cell. Biochem., 1998, 182, 101-108.
8. Elchelby, M.; Payette, P.; Michalisyn, E.; Cromlish, W; Collinschan, C.C.; Ramachandran, C.; Gresser, M.J.; Tremblay, M.L.; Kennedy, B.P. Structure of protein tyrosine phosphatase 1b in complex with inhibitors bearing two phosphotyrosine mimetics. Science, 1999, 283, 1544-1548.
9. Byon, J. C. H; Kusari, J.; Kusari, A. B. Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Mol. Cell. Biochem., 1998, 182, 101-108.
10. Montalibet, J.; Kennedy, B. P. Therapeutic strategies for targeting PTP1B in diabetes. Drug Discov. Today Therap. Strateg., 2005, 2, 129-135.
11. Robinson, D. D.; Winn, P. J.; Lyne, P. D.; Richards, W. G. Self-organizing molecular field analysis: a tool for structure-activity studies. J. Med. Chem., 1999, 42, 573-583.
12. Cramer, R. D., III; Patteerson, D. E.; Bunce, J.D. Comparative molecular field analysis (CoMFA). Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc., 1988, 110, 5959-5967.
13. Thareja, S.; Aggarwal, S.; Bhardwaj, T. R.; Kumar, M. Self organizing molecular field analysis of 2, 4-thiazolidinediones: A 3D-QSAR model for the development of human PTP 1B inhibitors. Eur. J. Med. Chem., 2010, 45, 2537-2546.
14. Aggarwal, S.; Thareja, S.; Bhardwaj, T. R.; Kumar, M. Self organizing molecular field analysis on pregnane derivatives as human steroidal 5 -reductase inhibitors. Steroids, 2010, 75, 411-418.
15. Liljebris, C.; Martinsson, J.; Tedenborg, L.; Williams, M.; Barker, E., Duffy, J. E.; Nygren, A.; James, S. Synthesis and biological activity of a novel class of pyridazine analogues as non-competitive reversible inhibitors of protein tyrosine phosphatase 1B (PTP1B). Bioorg. Med. Chem., 2002, 10, 3197-3212.
16. Thareja, S.; Aggarwal, S.; Bhardwaj, T. R.; Kumar, M. Self organizing molecular field analysis on a series of human 5 reductase inhibitors: Unsaturated 3-carboxysteroid. Eur. J. Med. Chem., 2009, 44, 4920-4925.
17. Aggarwal, S.; Thareja, S.; Bhardwaj, T. R.; Kumar, M. 3D-QSAR studies on unsaturated 4-azasteroids as human 5 -reductase inhibitors: a self organizing molecular field analysis approach. Eur. J. Med. Chem., 2009, 45, 476-481.
18. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. Development and use of quantum mechanical molecular models AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc., 1985, 107, 3902-3909.
19. Stewart, J. MOPAC: a semiempirical molecular orbital program. J. Comput. Aid. Mol. Des., 1990, 4, 1-105
20. Agarwal, A.; Taylor, E. W. 3-D QSAR for intrinsic activity of 5-HT1a receptor ligands by the method of comparative molecular field analysis. J. Comput. Chem., 1993, 14, 237-245.
21. Baurin, N.; Vangrevelinghe, E.; Allory, L.M. 3D-QSAR CoMFA study on imidazolinergic i2 ligands: a significant model through a combined exploration of structural diversity and methodology. J. Med. Chem., 2000, 43, 1109-1122.
22. Xu, M.; Zhang, A.; Han, S.; Wang, L. Studies of 3D-quantitative structure-activity relationships on a set of nitro aromatic compounds: CoMFA advanced CoMFA and CoMSIA. Chemosphere, 2002, 48, 707-715.
23. Pedretti, A.; Villa, L.; Vistoli, G. VEGA: a versatile program to convert, handle and visualize molecular structures on windows-based PCs. J. Mol. Graph. Model., 2002, 21, 47-49.
24. VEGA ZZ Release 2.0.5.52, Available from: http://www.ddl.unimi.it/vega/index2.htm
25. SOMFA2 v2.0.0 Available from: http://bellatrix.pcl.ox.ac.uk (2006).
26. Li, M.-Y.; Fang, H.; Xia, L. Pharmacophore based design, synthesis, biological evaluation, and 3D-QSAR studies of aryl-piperazines as [α]1-adrenoceptor antagonists. Bioorg. Med. Chem. Lett., 2005, 15, 3216-3219.
27. Kulkarni, S. S.; Gediya, L. K.; Kulkarni, V. M. Three-dimensional quantitative structure activity relationships (3D-QSAR) of antihyperglycemic agents. Bioorg. Med. Chem. Lett., 1999, 7, 1475-1485.
28. Puntambekar, D. S.; Giridhar, R.; Yadav, M. R. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and COMSIA Models. Eur. J. Med. Chem., 2008, 43, 142-154.
29. 2! J. Mol. Graph. Model., 2002, 20, 269-276.
30. Puntambekar, D.; Giridhar, R.; Yadav, M. R. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach. Bioorg. Med. Chem. Lett., 2006, 16, 1821-1827.